

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	Page 1, line 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2, line 22-41
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 3 line 43-61
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 3, line 62-63
Methods			
Study design	4	Present key elements of study design early in the paper	Page 4, 66-74
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4, 66-74
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page 4-5, line 75-94
		Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5, line 96-108
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 4-5, line 66-94

Bias	9	Describe any efforts to address potential sources of bias	Page 5-6, line 109-115
Study size	10	Explain how the study size was arrived at	Page 4, line 66- 70

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 5, line 96-108
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 5, line 98-108
		(b) Describe any methods used to examine subgroups and interactions	Page 5, line 109-110
		(c) Explain how missing data were addressed	Pag 6, line 111-115
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	Page 5-6, line 109-115
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 6, line 128-132
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	Page 14
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 7, line 133-136 and page 17
		(b) Indicate number of participants with missing data for each variable of interest	Page 6, line 111-112
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Page 7, line 137-138
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Page 7, line 137-138 and page 18
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 7 line 143-161 and page 19
		(b) Report category boundaries when continuous variables were categorized	Page 5, line 96-108
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 8, line 161-166
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 8, ine 168-170
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11, line 236-241
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 11, line 243-246
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11, line 227-234
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 6,line 24-126

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.